Table 1.
Relationship between Foxp3+RORγt+ T cells and baseline characteristics of patients
| Testing set (n = 226) | Validation set (n = 226) | |||||
|---|---|---|---|---|---|---|
| Factors | Foxp3+RORγt+ T low (n = 134) | Foxp3+RORγt+ T high (n = 92) | P | Foxp3+RORγt+ T low (n = 136) | Foxp3+RORγt+ T high (n = 90) | P |
| Age (years) | 0.635 | 0.303 | ||||
| Mean (± SD) | 60.7 (± 11.3) | 60.2 (± 11.8) | 59.4 (± 11.3) | 59.8 (± 12.5) | ||
| Gender | 0.6204 | 0.6906 | ||||
| Female | 42 | 26 | 36 | 26 | ||
| Male | 92 | 66 | 100 | 64 | ||
| Tumor size (cm) | 0.330 | 0.391 | ||||
| Mean (± SD) | 4.04 (± 2.12) | 3.64 (± 2.33) | 3.97 (± 2.17) | 3.59 (± 2.00) | ||
| Lauren’s classification | 0.1481 | 0.2403 | ||||
| Intestinal | 76 | 61 | 92 | 54 | ||
| Diffuse | 58 | 31 | 44 | 36 | ||
| Grade | 0.3049 | 0.2889 | ||||
| G1 | 5 | 1 | 3 | 5 | ||
| G2 | 31 | 17 | 25 | 20 | ||
| G3 | 98 | 74 | 108 | 65 | ||
| pTNM stage | 0.8350 | 0.1103 | ||||
| Stage I | 37 | 21 | 22 | 26 | ||
| Stage II | 25 | 20 | 41 | 20 | ||
| Stage III | 70 | 50 | 70 | 41 | ||
| Stage IV | 2 | 1 | 3 | 3 | ||
| Adjuvant chemotherapya | 0.8137 | 0.0550 | ||||
| Yes | 78 | 55 | 87 | 46 | ||
| No | 56 | 37 | 49 | 44 | ||
pTNM Pathologic tumor-node-metastasis
aPatients with adjuvant chemotherapy received at least one cycle of fluorouracil-based chemotherapy